What does KELA - Kempisch Laboratorium - Kela Laboratoria do?

KELA - Kempisch Laboratorium - Kela Laboratoria is registered with the CBE as active in: Vervaardiging van geneesmiddelen. Public Limited, started on 15 July 1941, 1 establishment.

What is the address of KELA - Kempisch Laboratorium - Kela Laboratoria?

The registered office of KELA - Kempisch Laboratorium - Kela Laboratoria is located at Sint Lenaartseweg 48, 2320 Hoogstraten.

Is KELA - Kempisch Laboratorium - Kela Laboratoria still active?

Yes. According to the CBE (29 October 2026) KELA - Kempisch Laboratorium - Kela Laboratoria is active, legal situation “Normale toestand”, started on 15 July 1941.

Is KELA - Kempisch Laboratorium - Kela Laboratoria registered on Peppol?

Yes, KELA - Kempisch Laboratorium - Kela Laboratoria is registered on the Peppol network with ID 0208:0403835645.

What is the enterprise number of KELA - Kempisch Laboratorium - Kela Laboratoria?

The enterprise number of KELA - Kempisch Laboratorium - Kela Laboratoria is BE0403835645.

Who are the directors of KELA - Kempisch Laboratorium - Kela Laboratoria?

According to the 2025 annual accounts, the directors of KELA - Kempisch Laboratorium - Kela Laboratoria are: Voxdale NV.

Is KELA - Kempisch Laboratorium - Kela Laboratoria a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 15 July 1941; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did KELA - Kempisch Laboratorium - Kela Laboratoria make in 2025?

KELA - Kempisch Laboratorium - Kela Laboratoria recorded a loss after taxes of € 1,194,162 in financial year 2025.

What is the revenue of KELA - Kempisch Laboratorium - Kela Laboratoria?

In its most recent annual accounts (2025), KELA - Kempisch Laboratorium - Kela Laboratoria reported revenue of € 55,218,027.

How much does an employee at KELA - Kempisch Laboratorium - Kela Laboratoria earn?

The average wage cost per full-time employee at KELA - Kempisch Laboratorium - Kela Laboratoria was € 78,000 in 2025: staff costs of € 20.4 million for 261.4 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does KELA - Kempisch Laboratorium - Kela Laboratoria have?

According to the 2025 annual accounts, KELA - Kempisch Laboratorium - Kela Laboratoria has 261.4 full-time equivalents (FTE).

KELA - Kempisch Laboratorium - Kela Laboratoria (Public Limited)

Q: When was KELA - Kempisch Laboratorium - Kela Laboratoria founded?

KELA - Kempisch Laboratorium - Kela Laboratoria was founded on 15 July 1941.

Dossier KELA - Kempisch Laboratorium - Kela Laboratoria, printed on 29 October 2026 from databakkes.be/en/0403835645/kela-kempisch-laboratorium-kela-laboratoria. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

KELA - Kempisch Laboratorium - Kela Laboratoria from Hoogstraten, company number BE0403835645, closed financial year 2025 with a result of € -1.2 million after tax. For that financial year KELA - Kempisch Laboratorium - Kela Laboratoria recorded revenue of € 55.2 million and equity of € 31.9 million. Compared with financial year 2024, the result moved from € 23.8 million to € -1.2 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 1, 2026.

What it is worth Healthy

€ 31.9 million

▼ 4% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -1.2 million

▼ still € 23.8 million profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1.4 million

▼ 83% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 23 million.

People and assets in 2025

Full-time equivalents

261.4

▲ 7.6 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 12.1 million in 2025, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 20.4 million

▲ 6% vs 2024

€ 78,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 9.6 million

▲ 2% vs 2024

Of which on lease € 9.4 million.

Debts at end 2025

Bank debt ≈ 16 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 14.7 million

▲ 22% vs 2024

€ 600,829 is repaid this year. At this pace the long-term loan is gone in ≈ 16 years.

Owed to suppliers

€ 7.2 million

▼ 4% vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 74 days on average.

Taxes and wages

€ 2.9 million

▲ 6% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 47,219,311 Revenue 2022: € 47,219,311 First fiscal year in the series	€ 47,005,254 Revenue 2023: € 47,005,254 Unchanged (€ 47,219,311) Unfavourable step	€ 50,685,866 Revenue 2024: € 50,685,866 ▲ 8% vs 2023 (€ 47,005,254) Favourable step	€ 55,218,027 Revenue 2025: € 55,218,027 ▲ 9% vs 2024 (€ 50,685,866) Favourable step	▲ 9%
Profit after taxes	€ -575,663 Profit after taxes 2022: € -575,663 First fiscal year in the series	€ -2,241,122 Profit after taxes 2023: € -2,241,122 ▼ € 1.7 million vs 2022 (€ -575,663) Unfavourable step	€ 23,751,179 Profit after taxes 2024: € 23,751,179 ▲ € 26 million vs 2023 (€ -2,241,122) Favourable step	€ -1,194,162 Profit after taxes 2025: € -1,194,162 ▼ € 24.9 million vs 2024 (€ 23,751,179) Unfavourable step	▼ € 24.9 million
Equity	€ 11,989,521 Equity 2022: € 11,989,521 First fiscal year in the series	€ 9,748,399 Equity 2023: € 9,748,399 ▼ 19% vs 2022 (€ 11,989,521) Unfavourable step	€ 33,129,498 Equity 2024: € 33,129,498 ▲ 240% vs 2023 (€ 9,748,399) Favourable step	€ 31,935,337 Equity 2025: € 31,935,337 ▼ 4% vs 2024 (€ 33,129,498) Unfavourable step	▼ 4%
Total debts	€ 39,793,554 Total debts 2022: € 39,793,554 First fiscal year in the series	€ 43,949,040 Total debts 2023: € 43,949,040 ▲ 10% vs 2022 (€ 39,793,554) Unfavourable step	€ 29,315,504 Total debts 2024: € 29,315,504 ▼ 33% vs 2023 (€ 43,949,040) Favourable step	€ 31,249,707 Total debts 2025: € 31,249,707 ▲ 7% vs 2024 (€ 29,315,504) Unfavourable step	▲ 7%
Cash	€ 957,588 Cash 2022: € 957,588 First fiscal year in the series	€ 2,069,036 Cash 2023: € 2,069,036 ▲ 116% vs 2022 (€ 957,588) Favourable step	€ 7,909,507 Cash 2024: € 7,909,507 ▲ 282% vs 2023 (€ 2,069,036) Favourable step	€ 1,370,407 Cash 2025: € 1,370,407 ▼ 83% vs 2024 (€ 7,909,507) Unfavourable step	▼ 83%
Land & buildings	€ 7,405,608 Land & buildings 2022: € 7,405,608 First fiscal year in the series	€ 7,071,349 Land & buildings 2023: € 7,071,349 ▼ 5% vs 2022 (€ 7,405,608) Unchanged	€ 6,740,494 Land & buildings 2024: € 6,740,494 ▼ 5% vs 2023 (€ 7,071,349) Unchanged	€ 6,456,969 Land & buildings 2025: € 6,456,969 ▼ 4% vs 2024 (€ 6,740,494) Unchanged	▼ 4%
Retained profit	€ 2,691,104 Retained profit 2022: € 2,691,104 First fiscal year in the series	€ 449,982 Retained profit 2023: € 449,982 ▼ 83% vs 2022 (€ 2,691,104) Unfavourable step	€ 24,201,161 Retained profit 2024: € 24,201,161 ▲ € 23.8 million vs 2023 (€ 449,982) Favourable step	€ 23,006,999 Retained profit 2025: € 23,006,999 ▼ 5% vs 2024 (€ 24,201,161) Unfavourable step	▼ 5%
Bank debt	€ 25,839,749 Bank debt 2022: € 25,839,749 First fiscal year in the series	€ 28,331,934 Bank debt 2023: € 28,331,934 ▲ 10% vs 2022 (€ 25,839,749) Unfavourable step	€ 12,094,442 Bank debt 2024: € 12,094,442 ▼ 57% vs 2023 (€ 28,331,934) Favourable step	€ 14,700,181 Bank debt 2025: € 14,700,181 ▲ 22% vs 2024 (€ 12,094,442) Unfavourable step	▲ 22%
Balance sheet total	€ 51,792,043 Balance sheet total 2022: € 51,792,043 First fiscal year in the series	€ 53,697,440 Balance sheet total 2023: € 53,697,440 ▲ 4% vs 2022 (€ 51,792,043) Unchanged	€ 62,445,003 Balance sheet total 2024: € 62,445,003 ▲ 16% vs 2023 (€ 53,697,440) Unchanged	€ 63,185,043 Balance sheet total 2025: € 63,185,043 ▲ 1% vs 2024 (€ 62,445,003) Unchanged	▲ 1%
Employees (FTE)	245.6 Employees (FTE) 2022: 245.6 First fiscal year in the series	252.3 Employees (FTE) 2023: 252.3 ▲ 6.7 vs 2022 (245.6) Unchanged	253.8 Employees (FTE) 2024: 253.8 ▲ 1.5 vs 2023 (252.3) Unchanged	261.4 Employees (FTE) 2025: 261.4 ▲ 7.6 vs 2024 (253.8) Unchanged	▲ 7.6

Key figures of KELA - Kempisch Laboratorium - Kela Laboratoria, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to KELA - Kempisch Laboratorium - Kela Laboratoria?

What happened at KELA - Kempisch Laboratorium - Kela Laboratoria in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 1, 2026 New annual accounts for financial year 2025: loss of € 1.2 million (▼ € 24.9 million vs 2024). Source: NBB ↗
2023 Voxdale NV became a director. NBB
Jul 15, 1941 Start of the company according to the CBE. KBO
Jul 1, 1941 New establishment in Hoogstraten. KBO

In short

From € 575,663 loss in 2022 to € 1.2 million loss in 2025.

Paid € 33,110 in corporate taxes since 2022.

Best year ever: 2024, with € 23.8 million profit.

Pays suppliers within 74 days on average.

Original PDFs at the National Bank ↗

Management

VOXDALE 93.1%

The stake of VOXDALE comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

KELA - Kempisch Laboratorium - Kela Laboratoria

ANUPCO LTD 200%

KELA DE LAS AMERICAS 199%

KELA HONG KONG LTD 100%

PHENIX PROPERTY 98%

Behind KELA - Kempisch Laboratorium - Kela Laboratoria is Voxdale NV. The shares are held by VOXDALE (93.1%). It owns 200% of ANUPCO LTD, 199% of KELA DE LAS AMERICAS, 100% of KELA HONG KONG LTD, 98% of PHENIX PROPERTY, 49% of SARL GROUPE PHARMACEUTIQUE MADANI KELA G.P.M.K. and 49% of KELA THAILAND LTD itself.

Directors

According to the 2025 annual accounts

Voxdale NV

Director · represented by Pascal BEYENS

Also active at: KELA VETERINARIA, PHENIX PROPERTY, Medicem

since 2023

Shareholders

VOXDALE

93.1%

Participations

ANUPCO LTD

200%

KELA DE LAS AMERICAS

199%

KELA HONG KONG LTD

100%

PHENIX PROPERTY

98%

SARL GROUPE PHARMACEUTIQUE MADANI KELA G.P.M.K.

49%

KELA THAILAND LTD

49%

Establishments

Establishment units

Physical locations of this company

Registered office

Sint Lenaartseweg 48

2320 Hoogstraten

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

KELA VETERINARIA same network

€ 7.4 million revenue · 2025

PHENIX PROPERTY same network

Medicem same network

VOXDALE same network

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0403.835.645
VAT number: BE 0403.835.645
Registered office: Sint Lenaartseweg 48, 2320 Hoogstraten
Names & denominations: KELA - Kempisch Laboratorium - Kela Laboratoria · Kela
Enterprise type: Rechtspersoon
Legal form: Public limited company
Legal situation: Normale toestand
Start date: 15 July 1941
Peppol: Active · Active since 1 Jan 2001
Activities · NACE: Vervaardiging van geneesmiddelen

View on CBE Public ↗ Annual accounts (NBB) ↗